Digital therapeutics provider Kaia Health has partnered with Italian pharmaceutical company Chiesi Group to offer its Kaia Health Chronic Obstructive Pulmonary Disease (COPD) rehabilitation app in Europe.
Under the partnership, Kaia Health COPD digital therapeutic will be highly focused on key markets in Europe, where its mobile app-based software platform can be delivered by healthcare professionals.
The app delivers customised daily training sessions, along with mindfulness and stress relief exercises, augmented with human coaching support and individualised therapy.
Konstantin Mehl, founder and president of Kaia Health, said: ‘Our strategic partnership with Chiesi, a growing global company with an established European commercial presence, brings a wealth of experience in navigating the respiratory health landscape in Europe, while expanding patient access to evidence-based, digital physical pulmonary rehabilitation.’
Ugo Di Francesco, chief executive officer of the Chiesi Group, added: ‘We’re pleased to partner with Kaia Health to complement and further strengthen our portfolio in the respiratory therapeutic area, expanding our ability to address patient care through a non-pharmacological approach.
‘We have been impressed with Kaia Health’s experience to date bringing impactful digital solutions to the European market and are looking forward to helping European COPD patients benefit from their expertise.’
Based in Italy, the Chiesi Group is a pharmaceutical company that operates in 29 countries. The group researches, develops and markets drugs for respiratory treatment, special care medicine and rare diseases. Chiesi’s research and development centre is based in Italy, and forms part of four other important R&D groups in France, the USA, the UK and Sweden.
©2026 All rights reserved LaingBuisson
